{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:25:43Z","timestamp":1776705943141,"version":"3.51.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:00:00Z","timestamp":1415404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12282-014-0575-6","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T16:27:58Z","timestamp":1415982478000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers"],"prefix":"10.1007","volume":"23","author":[{"given":"Kaolu","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Sato-Tadano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Ohuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"575_CR1","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"575_CR2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206\u201323.","journal-title":"Ann Oncol"},{"key":"575_CR3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736\u201347.","journal-title":"Ann Oncol"},{"key":"575_CR4","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16:5222\u201332.","journal-title":"Clin Cancer Res"},{"key":"575_CR5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00428-010-1009-2","volume":"458","author":"M Miyashita","year":"2011","unstructured":"Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, et al. Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch. 2011;458:65\u201372.","journal-title":"Virchows Arch"},{"key":"575_CR6","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1200\/JCO.2010.31.2835","volume":"29","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29:4273\u20138.","journal-title":"J Clin Oncol"},{"key":"575_CR7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","volume":"31","author":"A Prat","year":"2013","unstructured":"Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31:203\u20139.","journal-title":"J Clin Oncol"},{"key":"575_CR8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mds430","volume":"24","author":"G Cancello","year":"2013","unstructured":"Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013;24:661\u20138.","journal-title":"Ann Oncol"},{"key":"575_CR9","doi-asserted-by":"crossref","unstructured":"Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, et al. Survival outcomes in breast cancer patients with low estrogen\/progesterone receptor expression. Clin Breast Cancer. 2013","DOI":"10.1016\/j.clbc.2013.10.019"},{"key":"575_CR10","first-page":"155","volume":"11","author":"DC Allred","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155\u201368.","journal-title":"Mod Pathol"},{"key":"575_CR11","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997\u20134013.","journal-title":"J Clin Oncol"},{"key":"575_CR12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s12282-012-0387-5","volume":"21","author":"K Tamaki","year":"2014","unstructured":"Tamaki K, Ishida T, Tamaki N, Kamada Y, Uehara K, Miyashita M, et al. Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer. 2014;21:325\u201333.","journal-title":"Breast Cancer"},{"key":"575_CR13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","volume":"21","author":"VJ Bardou","year":"2003","unstructured":"Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973\u20139.","journal-title":"J Clin Oncol"},{"key":"575_CR14","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.26431","volume":"118","author":"KP Raghav","year":"2012","unstructured":"Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, et al. Impact of low estrogen\/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118:1498\u2013506.","journal-title":"Cancer"},{"key":"575_CR15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdq700","volume":"22","author":"H Anderson","year":"2011","unstructured":"Anderson H, Hills M, Zabaglo L, A\u2019Hern R, Leary AF, Haynes BP, et al. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol. 2011;22:1770\u20136.","journal-title":"Ann Oncol"},{"key":"575_CR16","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","volume":"23","author":"M Dowsett","year":"2005","unstructured":"Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer: a study from the IMPACT trialists. J Clin Oncol. 2005;23:2477\u201392.","journal-title":"J Clin Oncol"},{"key":"575_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10549-012-2265-4","volume":"136","author":"L Chen","year":"2012","unstructured":"Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, et al. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Res Treat. 2012;136:565\u201372.","journal-title":"Breast Cancer Res Treat"},{"key":"575_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000353099","volume":"85","author":"R Nishimura","year":"2013","unstructured":"Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, et al. Evaluation of factors related to late recurrence\u2014later than 10\u00a0years after the initial treatment\u2014in primary breast cancer. Oncology. 2013;85:100\u201310.","journal-title":"Oncology."},{"key":"575_CR19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.breast.2009.09.002","volume":"18","author":"R Stuart-Harris","year":"2009","unstructured":"Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. Breast. 2009;18:351\u20135.","journal-title":"Breast."},{"key":"575_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10549-013-2620-0","volume":"140","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, Wessels LF, et al. Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat. 2013;140:63\u201371.","journal-title":"Breast Cancer Res Treat"},{"key":"575_CR21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/annonc\/mdt575","volume":"25","author":"M Arnedos","year":"2014","unstructured":"Arnedos M, Drury S, Afentakis M, A\u2019Hern R, Hills M, Salter J, et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol. 2014;25:605\u201310.","journal-title":"Ann Oncol"},{"key":"575_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1477-7819-9-131","volume":"9","author":"R Nishimura","year":"2011","unstructured":"Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011;9:131.","journal-title":"World J Surg Oncol."}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-014-0575-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-014-0575-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-014-0575-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T10:43:46Z","timestamp":1566038626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-014-0575-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1007\/s12282-014-0575-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,8]]}}}